• ESCMID
  • CMI
  • EUCAST Newsletter
  • EUCAST News
Search
EUCAST
menu
Back Close
  • About EUCAST
    About EUCAST
    • Overview
    Close
    Organisation
    • Overview
    • Steering Committee
    • General Committee
    • EUCAST Statutes
    • National AST Committees (NAC)
    • Network Laboratories
    • Development Laboratories (EDL)
    • View all
    Subcommittees
    • Overview
    • Antimycobacterial Susceptibility Testing (AMST)
    • Antifungal Susceptibility Testing (AFST)
    • Veterinary Subcommittee on Antimicrobial Susceptibility Testing (VetCAST)
    • Phage Susceptibility Testing Subcommittee (PST)
    • Subcommittee on WGS and Phenotypic AST
    • View all
    Meetings
    • Overview
    • Steering Committee Meetings
    • General Committee Meetings
    Public Consultations
    • Overview
    SOPs
    • Overview
    IVDR and EUCAST
    • Overview
    News
    • Overview
    Publications and Presentations
    • Overview
  • Bacteria
    Bacteria
    • Overview
    Close
    Clinical Breakpoints and Interpretation
    • Overview
    • Clinical Breakpoint Tables
    • Definition of S, I and R
    • When there are no breakpoints?
    • Breakpoints in Brackets
    Guidance Documents
    • Overview
    Important Additional Information
    • Overview
    • Expert Rules
    • Expected Phenotypes
    • Resistance Detection
    MIC and Zone Distributions, ECOFFs
    • Overview
    Methodology and Instructions
    • Overview
    • Disk Diffusion and Quality Control
    • MIC Determination
    • Warnings
    • Media Preparation
    • Disk Diffusion Implementation
    • EUCAST Panels of Phenotypically Defined Strains
      • Overview
      • EUCAST Panel of S. pneumoniae and betalactam agents
      • EUCAST Panel of nine well characterized P. aeruginosa strains
    • IVDR and EUCAST
    • View all
    Rapid AST in blood culture
    • Overview
    • Rapid AST directly from blood culture bottles
    • Methods and Quality Control
    • Breakpoints for Rapid AST
    • Resistance Detection in RAST
    • RAST FAQ
    • RAST MIC:zone diameter correlations
    • RAST Publications
    • View all
    Development of Clinical Breakpoints and ECOFFs
    • Overview
    • About Clinical Breakpoints
    • Setting Breakpoints
    • Public Consultations
    • Rationale Documents
    • MIC:Zone Diameter correlations
    • Technical Notes on Antibacterial Agents
    • View all
    FAQ and EDL Services
    • Overview
    • FAQ
    • EDL MIC Testing Services
  • Mycobacteria (AMST)
    Mycobacteria (AMST)
    • Overview
    Close
    Subcommittee
    • Overview
    Clinical Breakpoints and Interpretation
    • Overview
    MIC distributions and ECOFFs
    • Overview
    Development of Clinical Breakpoints and ECOFFs
    • Overview
    • Public Consultations
    • Rationale Documents
    Methodology and Instructions
    • Overview
    • Reference Method
    • Mycobacteria FAQ
    • Warnings
    • IVDR and EUCAST
    Publications and Presentations
    • Overview
  • Fungi (AFST)
    Fungi (AFST)
    • Overview
    Close
    Subcommittee
    • Overview
    Clinical Breakpoints and Interpretation
    • Overview
    • Clinical breakpoint table
    • When there are no antifungal breakpoints
    Development of clinical breakpoints and ECOFFs
    • Overview
    • Rationale documents
    • Public consultations
    Methodology and Instructions
    • Overview
    • AST of Yeasts
    • AST of Moulds
    • AST of Dermatophytes
    • Warnings
    • Quality Control
    • IVDR and EUCAST
    • View all
    Publications and Presentations
    • Overview
    • Technical Notes on Antifungal Agents
  • VetCAST
    VetCAST
    • Overview
    Close
    Subcommittee
    • Overview
    MIC distributions and ECOFFs
    • Overview
    Development of clinical breakpoints and ECOFFs
    • Overview
    • Rationale Documents
    Publications and presentations
    • Overview
  • Industry
    Industry
    • Overview
    Close
  • Education
    Education
    • Overview
    Close
Search
  • ESCMID
  • CMI
  • EUCAST Newsletter
  • EUCAST News
Frequent searches
  • breakpoints
  • rationale documents
  • expected phenotypes
  • public consultation
  • endocarditis pathogens
  • guidance documents
Suggestions
  1. Home
  2. Search

Search Results

General

Reference Method

Reference Method The EUCAST reference method for the Mycobacterium tuberculosis complex is broth microdilution in Middlebrook 7H9. See following documents for further information. EUCAST reference protocol for MIC determination of anti-tuberculous agents against isolates of the Mycobacterium…

Get to know more

Industry

Information for pharmaceutical companies intending to bring new antimicrobial drugs to EUCAST for breakpoints The development of clinical breakpoints for new agents requires agreement and acceptance of the data generated in support of decisions on clinical breakpoints, wild type MIC distributions,…

Get to know more

Public consultations

Public consultation Public consultation is part of the EUCAST decision process. The consultation period is 4 - 12 weeks, and the dates of the beginning and end of the period is clearly stated. Previous public consultations with comments and EUCAST responses 2025 Archive Proposed new breakpoints for…

Get to know more

Document Archive

Document Archive Breakpoint tables for fungi QC tables Methodology Rationale documents Clinical breakpoints for fungi (v 11.0) - pdf file for printing (until 26 June, 2025) Clinical breakpoints for fungi (v 11.0) - excel file for screen (until 26 June, 2025) Clinical breakpoints for fungi (v 10.0) -…

Get to know more

Publications and Presentations

Publications by EUCAST in peer-reviewed journals 2025 2024 2023 2022 2021 2020 Archive Aminoglycoside breakpoints – the EUCAST approach and what this means for the clinician. C. Giske et al., Clin. Microbiol. Inf. 2025. Go to publication Rationale for contemporary antimicrobial treatment of…

Get to know more

Public Consultations

Public Consultations Public consultation is part of the EUCAST decision process. The consultation period is 4 - 12 weeks, and the dates of the beginning and end of the period is clearly stated. Current public consultations Subject Dates Description Carbapenem susceptibility testing and reporting -…

Get to know more

Document Archive

Document Archive Breakpoint tables QC tables Guidance documents Expert rules Rationale documents Disk diffusion methodology Disk diffusion validation RAST Expected phenotypes Broth microdilution Clinical breakpoints (v 14.0) - file for printing (1 Jan, 2024 - 31 Dec 2024) Clinical breakpoints (v…

Get to know more
© EUCAST 2025. All rights reserved EUCAST.
ContactSitemapPrivacy NoticeDisclaimerCookies

Welcome to the new EUCAST website!

We’ve prepared a short video to help you get familiar with the new layout and features.

Watch the video here